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Abstract  33 
In the UK the National Institute of Health and Care Excellence (NICE) advocates as a first line 34 
strategy the promotion of lifestyle programmes that attain the Chief Medical Officers 35 
recommended amount of physical activity in improving the health of people at risk of 36 
developing or already with type 2 diabetes. Many people may be prescribed pharmacological 37 
treatments to improve glucose management including both, oral and injectable therapies. NICE 38 
guidelines also support intensification of efforts to improve patient lifestyle along with these 39 
glucose-lowering therapies. However, there is a paucity of evidence in the available published 40 
literature examining the relation between glucose lowering therapies and exercise metabolism. 41 
This review examines the available research on potential interactions of oral and non-insulin 42 
injectable therapies with physical exercise or activity in people at risk or already with type 2 43 
diabetes. The conclusions of this review may inform healthcare professionals of the need to 44 
monitor patients more closely in their adaptation to both pharmacological therapy and physical 45 
activity.   46 
 47 
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49 
Novelty statement: 50 
 Independently, both lifestyle intervention programmes that encourage regular physical 51 
activity and glucose lowering oral or injectable therapies reduce the development of 52 
type 2 diabetes and improve glycaemia in those already with the condition.  53 
 This review summarises and consolidates available research on the observed effects of 54 
each class of oral and non-insulin injectable diabetes medication in combination with 55 
acute or chronic physical activity in people at risk of developing, or already with type 2 56 
diabetes.   57 
 This review may help clinicians better understand the possible interactions of some oral 58 
and injectable diabetes medications with physical activity. 59 
 60 
Introduction 61 
Currently in the United Kingdom 4.5 million people live with diabetes, of which 90% have type 62 
2 diabetes (T2DM) with an additional estimation of 1.1 million people that have undiagnosed 63 
diabetes (1). Furthermore, 4.75 million people are at increased risk of developing T2DM and 64 
11.5 million people are classed as overweight or obese with central adiposity based on waist 65 
circumference data (2). The latest physical activity report estimates that around 39% of the UK 66 
population have low levels of activity (3), which is a modifiable risk factor for obesity and 67 
many chronic conditions including T2DM and cardiovascular diseases (4,5).  68 
Increased physical activity is associated with a reduction in the risk of developing T2DM (6,7) 69 
and in people with T2DM, physical inactivity is associated with cardiovascular complications 70 
and mortality (8). In addition, physical activity improves physical exercise capacity, mental 71 
health and cardiovascular outcomes (9,10). In the United Kingdom, the National Institute of 72 
Health and Care Excellence (NICE) guidelines advocate positive lifestyle promotion for people 73 
at risk of developing or with T2DM (11). Lifestyle advice should always be offered for the 74 
management of T2DM, and if required oral or injectable glucose lowering therapies are 75 
recommended to improve blood glucose along with therapies to address other cardiovascular 76 
risk factors including hypertension and/or dyslipidaemia. A pragmatic approach to managing 77 
people with newly diagnosed T2DM is to simultaneously initiate pharmacotherapy by oral and 78 
injectable medications such as biguanides, sulfonylureas, thiazolidinediones (TZD), dipeptidyl 79 
peptidase-IV (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA) and 80 
sodium-glucose-cotransporter-2 (SGLT-2) inhibitors along with lifestyle advice (12). 81 
Healthcare professionals managing people with T2DM have an important role to encourage 82 
healthy behaviours including physical activity. However, there is evidence to suggest that 83 
healthcare professionals lack confidence in promoting and advising in relation to physical 84 
activity. This may be related to a number of factors such as medical or nursing education and 85 
training, knowledge and access to available resources, time constraints, patient-associated 86 
factors such as complications and willingness to engage in physical activity (13). Therefore, 87 
even though there is a strong evidence base to support physical activity in the management of 88 
T2DM and cardiovascular risk reduction, translation to clinical practice is often lacking (14). 89 
This review aims to examine the interaction between physical activity and commonly 90 
prescribed non-insulin glucose-lowering therapies. This review will not independently examine 91 
the efficacy of lifestyle programmes or of oral or injectable therapies on metabolic outcomes. 92 
Rather, this review will synopsise evidence to highlight issues pertaining to the management of 93 
people at risk of developing or already with T2DM adopting a physically active lifestyle whilst 94 
prescribed pharmacotherapy. 95 
 96 
Methods 97 
The authors undertook a detailed PubMed literature search for the following keywords: ‘type 2 98 
diabetes mellitus’, ‘T2DM’, ‘prediabetes’, ‘exercise’, ‘physical exercise’, ‘biguanides’, 99 
‘metformin’, ‘sulfonylurea’, ‘sulphonylurea’, ‘glinides’, ‘thiazolidinediones’, ‘GLP-1 receptor 100 
agonist’, ‘DPP-4’ and ‘SGLT-2’. The literature search was conducted independently by all 101 
authors in December 2017. Disagreements were discussed by the two lead authors (MLE; 102 
DMW) and solved with total consistency. If necessary, a third author (RMB) was consulted. 103 
Further, reference lists of systematic reviews, reviews and included and excluded articles were 104 
manually screened for studies of relevance. 105 
 106 
Biguanides 107 
Biguanides are the first-line oral glucose lowering therapy and can be used in combination with 108 
other therapies to treat hyperglycaemia without consequent hypoglycaemia. The only 109 
prescribed biguanide is metformin, which reduces hepatic tissue gluconeogenesis via 110 
attenuation of 5' AMP-activated protein kinase (AMPK) (15). Similarly, skeletal muscle 111 
contraction activates AMPK, enhances non-oxidative glucose disposal, and improves insulin-112 
stimulated glucose uptake by increased glucose transporter type 4 (GLUT-4) receptor activity 113 
(16). Thus, in a possible synergistic relationship, metformin and physical exercise might 114 
improve insulin sensitivity and/or glycaemia (17). However, metformin has also been shown to 115 
act as a mitochondrial membrane complex I inhibitor (18) and could potentially alter exercise 116 
metabolism and/or exercise tolerance. 117 
 118 
Glycaemia 119 
Prediabetes 120 
Several diabetes prevention programmes in China, USA, Finland and India detail separately the 121 
importance of metformin or lifestyle modification in reducing the development of T2DM (6,19–122 
21). Few studies have researched the combined impact of both metformin and intensive lifestyle 123 
treatment in people at risk of developing diabetes.  124 
Probably the largest exploration of the combined influence of metformin and intensive lifestyle 125 
intervention on progression to T2DM was reported in the Indian Diabetes Prevention 126 
Programme. In this 3-year study, 531 native Asian Indians with impaired glucose tolerance (age 127 
46 ± 6 years, BMI 25.8 ± 3.5 kg.m-2) were randomly allocated into a control group, lifestyle 128 
modification advice, metformin (~250 mg twice daily), or a combined lifestyle and metformin 129 
group. The primary outcome measure was diagnosis of T2DM after 3 years using World Health 130 
Organization criteria (fasting plasma glucose ≥7.0 mmol/l (126 mg/dl) or 2–h plasma glucose 131 
≥ 11.1 mmol/l (200 mg/dl)). The relative risk reduction was 28.5% with lifestyle modification 132 
(95% CI 20.5-37.3, p = 0.018), 26.4% with metformin (95% CI 19.1-35.1, p = 0.029) and 28.2% 133 
with combined lifestyle and metformin (95% CI 20.3-37.0, p = 0.022), compared to the control 134 
group. Thus, although both lifestyle advice and metformin reduced the incidence of diabetes in 135 
Asian Indians with impaired glucose tolerance there was no added benefit from combining 136 
them. However, the participants background physical activity patterns were heterogenous; 137 
those who were involved in physical labour, walked or cycled for >30 min/day or were already 138 
performing exercises regularly were asked to continue whereas those who were sedentary or 139 
performed light physical activity were advised and regularly motivated to walk briskly for at 140 
least 30 minutes each day. This was assessed by self-reported weekly physical activity levels 141 
and despite monthly telephone calls, no objective measurements were applied to further assess 142 
any changes in levels of physical activity. Further, given the low metformin dose administered, 143 
it would have been insightful to explore the influence of metformin dose on different physical 144 
activity groups, especially given the high degree of insulin resistance in South East Asians. In 145 
a follow-up analysis, the pattern of changes in  insulin  resistance and insulin to glucose ratio 146 
were  reported as similar  between  individual  intervention groups, though the data were 147 
collapsed and not individually reported in detail (22). 148 
More intensive clinical research trials on smaller numbers of well-controlled participants at risk 149 
of developing T2DM report a similar finding (23). Primarily Caucasian participants were 150 
randomised equally to a control group, metformin-only (progressing from 500-2000 mg/day by 151 
week 4), supervised three times a week exercise-only (cycling at 70% of pre-training heart rate 152 
peak (HRpeak) for 45 minutes per session and resistance exercises performed at 70% of 1-153 
repetition maximum) or a combined group. The addition of metformin to supervised exercise 154 
training in participants with low exercise capacity were not additive on insulin sensitivity, 155 
assessed by an euglycaemic-hyperinsulinaemic clamp technique. Indeed, there was a trend in 156 
the data of a 25-30% blunting of insulin sensitivity response but without changes in blood 157 
glucose concentrations in response to regular supervised exercise training when on metformin, 158 
compared to the control group. Other studies in the available literature described similar 159 
findings (24). Some researchers found alternate results where  habitual metformin treatment 160 
(1307 ±220 mg/day) in eight people with T2DM and two people with impaired fasting glucose 161 
did not blunt the acute insulin-sensitising effects of 45 minutes of high-intensity interval cycle 162 
exercise (4 × 4 minute intervals at 90% of HRpeak interspersed with 3 minute active recovery at 163 
70% HRpeak) (25).  164 
 165 
Type 2 Diabetes 166 
In a double-blind study comparing the glycaemic effects to 45 minutes of intermittent isometric 167 
one-legged exercise following 26 weeks of metformin (500 mg daily progressing to 1000 mg 168 
daily), rosiglitazone or placebo in T2DM, metformin increased the rate of skeletal muscle 169 
perfusion during exercise whilst on a euglycaemic-hyperinsulinaemic clamp, an effect possibly 170 
due to improvements in HbA1c over the 26-week treatment. However, like the placebo group, 171 
participants receiving metformin did not display any improvement in whole body glucose 172 
uptake or whole-body insulin sensitivity after 26 weeks (26). 173 
The glycaemic responses to 45 minutes cycling at 60% maximum oxygen uptake (VO2max) have 174 
been described in people with T2DM who either abstained (3 days) from, or took their habitual 175 
metformin (1000-3000 mg/day) treatment, or in a BMI- and age-matched group without T2DM 176 
(27). Exercise-induced blood glucose concentrations were stable in people without T2DM but 177 
decreased in people with T2DM when they had abstained from metformin treatment. 178 
Interestingly, there was a smaller decrease in blood glucose with exercise in the habitual 179 
metformin trial compared to when metformin was not taken. There was no influence of 180 
metformin on the exercise-induced increase in glucose rate of appearance and rate of 181 
disappearance, yet values were lower in the diabetes group compared to people without T2DM. 182 
However, notwithstanding this, after correcting for glucose mass action effects on glucose 183 
uptake, metabolic clearance rate was higher in diabetes participants when they took metformin 184 
compared to when they abstained from metformin. Similarly, people with T2DM treated with 185 
metformin (~2000 mg/day) exhibited a blunted reduction in blood glucose concentrations 186 
compared to the placebo arm during incremental cycle exercise to exhaustion. Following 187 
exercise, the rise in blood glucose with a post-exercise standardised lunch was lower in those 188 
taking metformin compared to those on placebo (17). 189 
In a retrospective analysis, previously inactive people with T2DM who participated in 22 weeks 190 
of aerobic exercise training whilst on metformin (before training 1,603 ± 600 vs after training 191 
1,654 ± 616 mg/day) improved their HbA1c (−6.3 mmol/mol, 95% CI −11.5, −1.1; 0.57%, 95% 192 
CI −1.05, −0.10) more than those who performed training without metformin (−1.9 mmol/mol, 193 
95% CI −8.5, 4.7; 0.17, 95% CI −0.78, 0.43). There was no influence of metformin on HbA1c 194 
in those who performed only resistance exercise training three times a week. When participants 195 
performed both combined aerobic and resistance exercise training, metformin did not blunt the 196 
training-induced reduction in HbA1c.  Indeed, there was a greater reduction in fasting glucose 197 
seen in those participants who took metformin (−1.47 mmol/l vs −0.52 mmol/l). A caveat to the 198 
results of this study is that participants were not randomised to treatment groups and those 199 
receiving metformin had a significantly longer duration of diabetes (28). 200 
Finally, the impact of metformin treatment on interstitial glucose concentrations of people with 201 
T2DM during brisk walking (50 minutes) has been examined. Participants who were habitually 202 
taking metformin completed four experimental conditions comprising of taking metformin: (i) 203 
in the morning and evening without exercise, (ii) in the morning and in the evening with 204 
exercise, (iii) in the evening only after walking, and (iv) in the morning only with walking. 205 
Glucose was measured for 72 hours using a continuous glucose monitoring system with 206 
standardised meals provided. The inclusion of walking to bi-daily metformin treatment 207 
increased mean 2-hour incremental post-prandial area under the curve but did not affect daily 208 
mean glucose or fasting glucose concentrations. A reduction in metformin dose by removal of 209 
morning or evening metformin did not alter the increase in postprandial glucose levels with 210 
walking nor affect mean glucose concentrations (29). 211 
 212 
Lipid metabolism 213 
Obesity, insulin resistance and T2DM are intimately associated with derangements in lipid 214 
metabolism. Increased levels of fatty acids inhibit insulin-stimulated glucose transport and/or 215 
glucose breakdown on skeletal muscle. Dysregulation in skeletal muscle fatty acid metabolism 216 
involves increased fatty acid transport, reduced fatty acid oxidation and an accumulation of 217 
reactive lipid species like diacylglycerols and ceramides. It is a common finding that acute 218 
moderate intensity exercise elevates whole body lipid utilisation, along with increasing use of  219 
hepatic and skeletal muscle triglyceride pools. Chronic physical training increases lipid 220 
combustion capacity compared to the untrained state and enhances the use of non-esterified 221 
fatty acids (NEFA), lowers circulating lipids (LDL-cholesterol, triglycerides) and raises HDL-222 
cholesterol (30). Reducing ectopic lipids such as NEFA and increasing HDL improve insulin 223 
signalling, decreases the risk of developing and the progression of T2DM and exerts a beneficial 224 
effect on cardiovascular disease risk (31).  225 
Metformin reduces lipid storage in human skeletal muscle (32,33) and aids improvement in 226 
whole body lipid turnover, promoting fatty acid oxidation. In rats, 8 weeks of metformin 227 
treatment reduced hyperglycaemia, and skeletal muscle FAT/CD36 transporter abundance, 228 
ceramide and diacylglyceride content (34). In humans, chronic metformin treatment has also 229 
been shown to reduce plasma triglycerides and/or total and LDL-cholesterol concentrations 230 
(35,36) though plasma free fatty acids (FFA) were unchanged. However, research studies have 231 
demonstrated no change on FFA turnover or oxidation but chronic metformin treatment has 232 
been shown to improve body weight (26).  233 
Thus, the combined effect of both metformin and regular exercise might increase fatty acid 234 
metabolism more than either effect alone. Indeed, in a combined lifestyle modification with 235 
metformin participants demonstrated a significantly greater reduction in total cholesterol, LDL- 236 
and increase in HDL-cholesterol compared to lifestyle modification alone (37,38). In the Indian 237 
Diabetes Prevention trial, the proportions of participants with elevated LDL-cholesterol 238 
decreased in all active treatment groups but not in the control group. Increased weight loss from 239 
pre-trial values was evident in participant groups with lifestyle modification plus metformin 240 
(39). Combined treatments may also be beneficial in increasing insulin sensitivity (40) and in 241 
treatment motivation.  Interestingly there is some evidence of elevated lipid oxidation during 242 
submaximal walking in people with T2DM on metformin (evidenced by a lower respiratory 243 
exchange ratio) compared to walking alone (17) with similar findings in people without T2DM 244 
(41). 245 
 246 
Exercise Tolerance 247 
There is limited evidence of metformin influencing exercise tolerance. Increased exercise-248 
induced lactate concentrations have been shown in some studies when participants were taking 249 
metformin (17,24). However, this was not shown at rest (35). Elevated heart rate (17) with 250 
higher self-reported ratings of perceived exertion to exercise  have been also recorded (17,24).  251 
This may have implications on exercise tolerance in people at risk of developing T2DM and 252 
those already with the condition. 253 
 254 
Metformin and Physical Activity: In people at risk of developing T2DM, addition of 255 
metformin to a lifestyle modification programme or supervised exercise training did not alter 256 
long-term alterations in glycaemia more than metformin only or physical training alone nor 257 
impact on numbers progressing to T2DM.  258 
In an acute exercise setting, metformin can reduce the decline in blood glucose in people with 259 
T2DM but the glycaemic effects of metformin whilst performing exercise, in people at risk or 260 
with T2DM appear transient and minor. Longer-term combined treatments seem equivalent to 261 
both training or metformin alone. In some studies, metformin can alter the participants’ 262 
perceived exertion  to acute exercise which might impact exercise tolerance.  263 
 264 
Sulfonylureas 265 
Sulfonylureas are an established oral glucose lowering therapy and continue to be used in the 266 
clinical practice for the management of people with T2DM (12). They act to depolarise the 267 
pancreatic β-cell by binding ATP-sensitive potassium channels and inducing insulin release. 268 
Though there is debate regarding cardiovascular safety, sulfonylureas remain the most common 269 
second-line oral hypoglycaemic agent prescribed in people with T2DM (11,12). Common side-270 
effects of sulfonylureas include weight gain and hypoglycaemia, particularly in the older adult 271 
(42).  272 
 273 
Glycaemic interactions of physical exercise and sulfonylureas 274 
At the onset of exercise, there is a temporary mismatch between glucose uptake by the working 275 
musculature and release from hepatic glycogen stores that affects blood glucose (43). In 276 
particular for continuous low-intensity exercise, people treated with sulfonylureas may be at a 277 
higher risk of exercise-induced hypoglycaemia especially if initial blood glucose concentrations 278 
are low at the onset of exercise (44). The combination of glibenclamide and exercise increases 279 
the risk of hypoglycaemia by 33% compared to glibenclamide alone and by 83% compared to 280 
exercise alone (45). Greater circulating insulin concentrations were found when participants 281 
performed a 60-min ergometer cycle exercise at 57 ± 3% of VO2max after taking 7 mg of 282 
glibenclamide. Furthermore, the rate of reduction in blood glucose was faster and the glucose 283 
appearance rate in the circulation lower during exercise combined with glibenclamide 284 
compared with exercise alone (46). In another study, the administration of 3 mg of glimepiride 285 
or 10 mg of glibenclamide one hour prior to moderate intensity (heart rate-120 bpm) cycle 286 
exercise resulted in a lower three-hour blood glucose area under the curve in 167 people with 287 
T2DM compared to those who did not exercise with similar results for both medications. Also, 288 
exercise was associated with a decrease in C-peptide and insulin area under the curve in the 289 
glimepiride group, but the same effect was not found with glibenclamide treatment indicating 290 
a suppression in endogenous insulin release with glibencamide (47). The above studies suggest 291 
vigilance in monitoring glycaemic responses during exercise for people with T2DM on 292 
glibenclamide.  293 
 294 
Lipids  295 
Sulfonylureas may impact on cardiovascular disease risk by influencing body mass, blood 296 
pressure and lipid metabolism (48). Contrary to metformin users, sulfonylurea users usually 297 
experience some weight gain (3-5 kg) and an increased blood pressure during a 12-month period 298 
(12). A recent meta-analysis concluded that the effect of sulfonylureas on lipids is small, 299 
however a statistically significant increase in FFA and triglycerides but decrease in HDL and 300 
LDL was detected (49). However, no evidence exists on the impact of both exercise and 301 
sulfonylureas on lipid metabolism over each treatment alone. 302 
 303 
 304 
 305 
Exercise Metabolism and Tolerance:  306 
We found no direct evidence of altered exercise tolerance resulting from sulfonylurea therapy, 307 
though the indirect impact of hypoglycaemia would be factor.  308 
 309 
Sulfonylurea and physical activity: Sulfonylureas should be taken with caution around acute 310 
exercise, since the combined influence of both can rapidly decrease blood glucose levels and 311 
lead to hypoglycaemia.  312 
 313 
Glinides 314 
Similar to sulfonylureas, glinides work by binding to pancreatic β-cell ATP-sensitive K+-315 
channels to induce insulin secretion. Results from the placebo cohort of the Nateglinide And 316 
Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study revealed 317 
small but significant associations between increases in accelerometer-recorded physical activity 318 
levels and a reduction in oral glucose tolerance test (OGTT) 2-h glucose values. This 319 
relationship was lost in participants taking both nateglinide and valsartan, though it is difficult 320 
to ascribe the observed effect to either of the two medications in this study and how both of 321 
them interacted with exercise (50). 322 
 323 
Glinides and Physical Activity : There is no evidence to detail the impact of glinides on 324 
physical exercise and metabolic outcomes. 325 
 326 
Thiazolidinediones  327 
Glucose and Lipids 328 
Currently, pioglitazone is the only TZD licensed for use. Troglitazone was withdrawn following 329 
individual cases of liver injury and failure of therapy and rosiglitazone was withdrawn due to 330 
an association with increased cardiovascular events (51). Generally, TZDs activate peroxisome-331 
proliferator-activated receptor gamma (PPAR-γ) (51). and increase fuel use thus, reducing FFA 332 
concentration in plasma and excessive accumulation in the liver, enhancing hepatic and skeletal 333 
muscle insulin sensitivity (12). There are a limited number of studies measuring the effect of 334 
pioglitazone in combination with exercise in relation to glycaemic control. The Insulin 335 
Resistance Intervention After Stroke (IRIS III) study included 1298 people with T2DM who 336 
were prescribed their normal diabetes treatment along with pioglitazone for 20 weeks. 337 
Participants were stratified according to level of exercise (‘never’, ‘sometimes’ or ‘regularly’). 338 
Glycaemic control, blood pressure and lipid levels improved with increasing self-rated levels 339 
of exercise. The impact of exercise on insulin resistance was positively correlated to the 340 
exercise level, however pioglitazone treatment is recommended independent from the exercise 341 
level of the study participants (52). In another study, people that were newly diagnosed or had 342 
diet-treated T2DM were randomised to rosiglitazone (4 mg, twice a day), metformin (1g, twice 343 
a day) or placebo. Those on rosiglitazone experienced increased insulin responsiveness in 344 
resting skeletal muscle (38% increase) and a doubling of glucose uptake during one-legged 345 
exercise using 10% maximum force (26).  346 
 347 
Exercise Metabolism and Tolerance 348 
A small trial of 24 participants found that after 24 weeks, people with T2DM receiving 349 
pioglitazone had significantly increased cardiac stroke volume and ejection fraction (53). 350 
Although no longer prescribed, rosiglitazone (4 mg per day for four months) was associated 351 
with an improved peak rate of oxygen consumption (VO2peak) compared to placebo in 352 
individuals with previously sedentary lifestyles (54). Interestingly, the change in VO2peak was 353 
correlated with improved insulin sensitivity (54).  354 
 355 
Thiazolidinediones and Physical Activity : While evidence in this area is limited, published 356 
findings to date suggest that in combination with exercise, some TZDs might improve exercise 357 
capacity and reduce cardiovascular disease risk. 358 
 359 
Incretin-based therapies 360 
Incretins are gut-derived post-prandial hormones secreted by the distal jejunum and ileum, 361 
which stimulates insulin release from the β-cells, inhibits glucagon release from the α-cells, 362 
delays gastric emptying and increases early satiety. This endogenous response is impaired in 363 
T2DM. The two classes of approved therapies which potentiate the incretin effect are GLP-364 
1RA and DPP-4 inhibitors. GLP-1RAs potentiate the incretin effect directly, whilst DPP-4 365 
inhibitors prevent incretin hormone degradation (12). Few studies have examined these 366 
therapies in conjunction with physical exercise. 367 
 368 
GLP-1 Receptor agonists 369 
Glycaemia 370 
In a sample of overweight participants with T2DM and suboptimal glycaemic control, 371 
liraglutide in combination with a 16-week exercise training programme (consisting of cycling 372 
and resistance exercises) demonstrated greater reductions in fasting plasma glucose compared 373 
to a placebo and training arm (-3.4 ± 2.3 vs -0.3 ± 2.6 mmol.L-1, p<0.05), and HbA1c (2.0% ± 374 
1.2% vs. 0.3% ± 0.9%, p<0.05) (55). Liraglutide in combination with exercise training also 375 
improved body mass and blood pressure compared to a placebo and exercise training group 376 
although similar changes in estimated percent body fat, VO2peak and quality of life markers were 377 
noted between the groups in response to exercise training (55). 378 
 379 
Cardiovascular alterations and exercise tolerance 380 
Cardiovascular function may be impaired in people with T2DM and increases the likelihood of 381 
cardiovascular disease. Although dependent on characteristics such as exercise duration, 382 
intensity and length of training, exercise has been shown to improve several factors involved in 383 
cardiovascular function in T2DM (56). In a double-blind, placebo-controlled study, liraglutide 384 
treatment for 12 weeks did not improve left ventricular ejection fraction during dobutamine 385 
stress echocardiography in people with stable coronary heart disease. Furthermore, no changes 386 
were observed in systolic function and/or exercise performance in a graded exercise test (56). 387 
Twelve weeks of exenatide treatment was associated with improved diastolic function and 388 
arterial stiffness, but not endothelial function in a double-blind study of 23 people with 389 
uncomplicated T2DM randomised to receive exenatide or placebo. Participants performed 390 
graded exercise tests before and after treatment but neither VO2peak  nor VO2 kinetics changed 391 
as a result of exenatide treatment (58). Interestingly, a combination of cycling and resistance 392 
exercise training (3 times a week for 60 mins per session for 16 weeks) with liraglutide or 393 
placebo did not alter left ventricle or atrial dimensions, systolic measurements or heart rate in 394 
people with T2DM. However, liraglutide blunted the improvement in diastolic function with 395 
training as evidenced by a lack of change in early diastolic mitral annular tissue velocity and 396 
the ratio of early and atrial mitral annular myocardial tissue velocities, which estimate the 397 
relative contribution of the passive left ventricular filling to the active contribution. Therefore, 398 
currently, despite the observed benefits on glycaemia, the impact of liraglutide on 399 
cardiovascular changes with regular physical exercise is complex and demands further 400 
investigation. 401 
 402 
GLP-1RA and Physical Activity: Combined, there appear to be some positive effects on 403 
glycaemia and exercise capacity with some impact of GLP-1RA on cardiovascular indices.  404 
 405 
Dipeptidyl peptidase-4 inhibitors  406 
Within this literature review, we found no human studies that assessed the combined impact of 407 
DPP-4 inhibitors and exercise on metabolic outcomes. Prediabetic mice who undertook 408 
swimming exercise or were given DPP-4 inhibitors over 8 weeks both independently showed 409 
significant improvements in body weight, fasting and random plasma glucose plus improved 410 
glucose tolerance and insulin sensitivity compared with mice that did not exercise or receive 411 
DPP-4 intervention (59). Thus, human trials that explore DPP-4 inhibitor treatment and exercise 412 
training are warranted.  413 
 414 
DPP-4 inhibitors and Physical Activity: There is no evidence for an influence of DPP-4 415 
inhibitors on physical activity in humans. 416 
 417 
Sodium-glucose-cotransporters-2 (SGLT-2) inhibitors 418 
The SGLT-2 inhibitors prevent the re-uptake of glucose within the proximal convoluted tubule 419 
of the kidney, thereby increasing urinary glucose excretion. The reduced renal glucose re-420 
absorption caused by SGLT-2 inhibitors results in the passage of greater volumes of urine by 421 
osmosis, with patients producing up to 470 ml more urine per day (60). However, blood flow 422 
to kidneys of ~1.0 litre per minute is remarkably stable during exercise, representing 423 
approximately 20-25% of the cardiac output at rest, and due to sympathetic nerve-induced renal 424 
vasoconstriction 3-5 % of total blood volume during exercise (61). During exercise, water loss 425 
occurs, with exhaled moist breath and sweat contributing to the 1-1.5 litres per hour loss in 426 
temperate environments (62). Dehydration is a concern but perhaps more serious, and 427 
potentially exacerbated by dehydration is the condition of euglycaemic diabetic ketoacidosis, 428 
arising because of ketone formation due to a decreased insulin-to-glucagon ratio in participants 429 
using SGLT-2 inhibitors (63). Sub-maximal sustained exercise, especially in the unfed 430 
condition, may also lead to increased lipid use and consequent ketone body formation. Studies 431 
directly investigating the potential for accentuated ketone body formation and hydration status 432 
on SGLT-2 inhibitor treatment are warranted. 433 
SGLT-2 inhibitors are considered cardio-protective, with their use associated with reduced 434 
body weight, blood pressure, uric acid levels and endothelial oxidative stress (64). Moreover, 435 
SGLT-2 inhibitors affect lipid levels also, with canagliflozin increasing HDL and LDL levels, 436 
and reducing serum triglycerides (65). Though, physical exercise improves cardiovascular and 437 
respiratory systems we found no published studies directly assessing the combined effect of 438 
SGLT-2 inhibitors and exercise. Such research is needed as the combined use of SGLT-2 439 
inhibitors and exercise may confer greater glycaemic or cardiovascular benefits but at a 440 
potential expense of increased potential for diabetic ketoacidosis or renal function impairment.  441 
 442 
SGLT-2 inhibitors and Physical Activity: No human studies have yet investigated the effects 443 
of SGLT-2 drugs combined with exercise. 444 
 445 
Future directions 446 
Many gaps exist in the published literature relating to our understanding of the impact of 447 
different oral and non-insulin injectable therapies (as monotherapy and in combination), in 448 
individuals wishing to improve their lifestyle by incorporating physical activity (Table 1). 449 
Future areas of investigation should explore  450 
 risk of potential hypoglycaemic episodes in acute exercise in people taking 451 
sulfonylureas.  452 
 long-term studies to investigate the effects of GLP-1RA combined with exercise on 453 
cardiovascular indices.  454 
 studies investigating SGLT-2 inhibitors interaction with exercise and potential ketone 455 
formation in people with T2DM might be warranted to avoid diabetic ketoacidosis. 456 
 457 
Conclusion 458 
Though the current incidence and future growth patterns of T2DM are disappointing, the 459 
healthcare professional has two first-line treatments to improve patient outcomes i.e. 460 
pharmacotherapy and promotion of positive lifestyle behaviours. To date there is limited 461 
understanding of the interactions between oral/injectable agents in people at risk or already 462 
living with T2DM that are also encouraged to engage in physical activity. The current review 463 
advocates physical exercise for people at risk of developing- or already with T2DM whilst using 464 
drug monotherapy with some caveats. Healthcare professionals should promote physical 465 
activity but be vigilant in monitoring patients and be prepared to make prudent adjustments to 466 
medications or physical activities if adverse events are experienced. 467 
 468 
References: 469 
1.  Diabetes UK. Facts and Starts [Internet]. [cited 2018 Jan 30]. Available from: 470 
https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-471 
storage/migration/pdf/DiabetesUK_Facts_Stats_Oct16.pdf 472 
2.  Mainous AG, Tanner RJ, Baker R, Zayas CE, Harle CA. Prevalence of prediabetes in 473 
England from 2003 to 2011: Population-based, cross-sectional study. BMJ Open. 474 
2014;4(6).  475 
3.  BHF. Physical inactivity and sedentary behaviour report 2017. Br Hear Found 476 
[Internet]. 2017;10. Available from: 477 
https://www.bhf.org.uk/publications/statistics/physical-inactivity-report-2017 478 
4.  Warburton D, Nicol C, Bredin S. Health benefits of physical activity: the evidence. Can 479 
Med Assoc J. 2006;174(6):801–9.  480 
5.  Warburton D, Nicol C, Bredin S. Prescribing exercise as preventive therapy. Cmaj. 481 
2006;174(7):961–74.  482 
6.  Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et 483 
al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or 484 
metformin. N Engl J Med. 2002;346(6):393–403.  485 
7.  Folsom  a R, Kushi LH, Hong CP. Physical activity and incident diabetes mellitus in 486 
postmenopausal women. Am J Public Health. 2000;90(1):134–8.  487 
8.  Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity, 488 
cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes 489 
Care. 2005;28(4):799–805.  490 
9.  Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. 491 
Physical activity/exercise and diabetes: A position statement of the American Diabetes 492 
Association. Diabetes Care. 2016;39(11):2065–79.  493 
10.  Warburton D, Bredin S. Health benefits of physical activity: A systematic review of 494 
current systematic reviews. Curr Opin Cardiol. 2017;32(5):541–56.  495 
11.  NICE. Type 2 diabetes in adults: management [Internet]. National Institute for Health 496 
and Care Excellence. 2015 [cited 2018 Apr 4]. p. 1–57. Available from: 497 
https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-498 
management-1837338615493 499 
12.  Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. 500 
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus 501 
Management. Front Endocrinol (Lausanne). 2017 Jan 24;8.  502 
13.  Oberg EB, Frank E. Physicians’ health practices strongly influence patient health 503 
practices. J R Coll Physicians Edinb. 2011;39(4):290–1.  504 
14.  National Institute for Health and Care Excellence. Algorithm for blood glucose 505 
lowering therapy in adults with type 2 diabetes. NICE Guid [Internet]. 2017;(December 506 
2015):2017. Available from: 507 
https://www.nice.org.uk/guidance/ng28/resources/algorithm-for-blood-glucose-508 
lowering-therapy-in-adults-with-type-2-diabetes-pdf-2185604173 509 
15.  Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of 510 
hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A 511 
systematic review. Diabetologia. 2006;49(3):434–41.  512 
16.  Johnson  a B, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, et al. The 513 
impact of metformin therapy on hepatic glucose production and skeletal muscle 514 
glycogen synthase activity in overweight type II diabetic patients. Metabolism. 515 
1993;42(9):1217–22.  516 
17.  Boulé NG, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, et al. Metformin 517 
and exercise in type 2 diabetes: Examining treatment modality interactions. Diabetes 518 
Care. 2011;34(7):1469–74.  519 
18.  Owen MR, Doran E, Halestrap AP. Complex 1 of the Mitochondrial Respiratory 520 
Chain. Biochem J. 2000;614:607–14.  521 
19.  Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, et al. Effects of Diet and 522 
Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da 523 
Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr 1;20(4):537–44.  524 
20.  Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et 525 
al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects 526 
with Impaired Glucose Tolerance. N Engl J Med. 2001 May 3;344(18):1343–50.  527 
21.  Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian 528 
Diabetes Prevention Programme shows that lifestyle modification and metformin 529 
prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance 530 
(IDPP-1). Diabetologia. 2006;49(2):289–97.  531 
22.  Snehalatha C, Mary S, Selvam S, Kumar CKS, Shetty SBA, Ramachandran A. 532 
Changes in insulin secretion and insulin sensitivity in relation to the glycemic 533 
outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention 534 
Programme-1 (IDPP_1). Diabetes Care. 2009;32(10):1796–801.  535 
23.  Malin SK, Gerber R, Chipkin SR, Braun B. Independent and combined effects of 536 
exercise training and metformin on insulin sensitivity in individuals with prediabetes. 537 
Diabetes Care. 2012;35(1):131–6.  538 
24.  Malin SK, Stephens BR, Sharoff CG, Hagobian TA, Chipkin SR, Braun B. 539 
Metformin’s Effect on Exercise and Postexercise Substrate Oxidation. Int J Sport Nutr 540 
Exerc Metab. 2010 Feb;20(1):63–71.  541 
25.  Ortega JF, Hamouti N, Fernández-Elías VE, de Prada MVG, Martínez-Vizcaíno V, 542 
Mora-Rodríguez R. Metformin does not attenuate the acute insulin-sensitizing effect of 543 
a single bout of exercise in individuals with insulin resistance. Acta Diabetol. 544 
2014;51(5):749–55.  545 
26.  Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, et al. 546 
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal 547 
muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 548 
2002;51(12):3479–85.  549 
27.  Hansen M, Palsøe MK, Helge JW, Dela F. The effect of metformin on glucose 550 
homeostasis during moderate exercise. Diabetes Care. 2015;38(2):293–301.  551 
28.  Boulé NG, Kenny GP, Larose J, Khandwala F, Kuzik N, Sigal RJ. Does metformin 552 
modify the effect on glycaemic control of aerobic exercise, resistance exercise or both? 553 
Diabetologia. 2013;56(11):2378–82.  554 
29.  Myette-Côté É, Terada T, Boulé NG. The Effect of Exercise with or Without 555 
Metformin on Glucose Profiles in Type 2 Diabetes: A Pilot Study. Can J Diabetes. 556 
2016;40(2):173–7.  557 
30.  Horowitz JF, Klein S. Lipid metabolism during endurance exercise. Am J Clin Nutr. 558 
2000 Aug 1;72(2):558S–563S.  559 
31.  Boreham CA, Ferreira I, Twisk JW, Gallagher AM, Savage MJ, Murray LJ. 560 
Cardiorespiratory fitness, physical activity, and arterial stiffness: The Northern Ireland 561 
young hearts project. Hypertension. 2004;44(5):721–6.  562 
32.  Driscoll SD, Meininger GE, Ljungquist K, Hadigan C, Torriani M, Klibanski A, et al. 563 
Differential Effects of Metformin and Exercise on Muscle Adiposity and Metabolic 564 
Indices in Human Immunodeficiency Virus-Infected Patients. J Clin Endocrinol Metab. 565 
2004;89(5):2171–8.  566 
33.  Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, et al. Regulation of 567 
skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: 568 
Relationship to glucose disposal. Metabolism. 2003;52(5):540–6.  569 
34.  Smith AC, Mullen KL, Junkin KA, Nickerson J, Chabowski A, Bonen A, et al. 570 
Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt 571 
the progression of high-fat diet-induced hyperglycemia. AJP Endocrinol Metab. 572 
2007;293(1):E172–81.  573 
35.  Cusi K, Consoli A, DeFronzo R. Metabolic Effects of Metformin on Glucose and 574 
Lactate Metabolism in Noninsulin-Dependent Diabetes Mellitus. J Clin Endocrinol 575 
Metab. 1996;(August).  576 
36.  Rains SG, Wilson G a, Richmond W, Elkeles RS. The reduction of low density 577 
lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc 578 
Med. 1989;82(February):93–4.  579 
37.  Andreadis E, Katsanou P, Georgiopoulos D, Tsourous G, Yfanti G, Gouveri E, et al. 580 
The Effect of Metformin on the Incidence of Type 2 Diabetes Mellitus and 581 
Cardiovascular Disease Risk Factors in Overweight and Obese Subjects – The Carmos 582 
Study. Exp Clin Endocrinol Diabetes. 2008 Dec 3;117(04):175–80.  583 
38.  Clarson CL, Mahmud FH, Baker JE, Clark HE, Mckay WM, Schauteet VD, et al. 584 
Metformin in combination with structured lifestyle intervention improved body mass 585 
index in obese adolescents, but did not improve insulin resistance. Endocrine. 2009 586 
Aug 23;36(1):141–6.  587 
39.  Rynders C, Weltman A, Delgiorno C, Balagopal P, Damaso L, Killen K, et al. Lifestyle 588 
intervention improves fitness independent of metformin in obese adolescents. Med Sci 589 
Sports Exerc. 2012;44(5):786–92.  590 
40.  DPPR. The Diabetes Prevention Program: Description of lifestyle intervention. 591 
Diabetes Care. 2002;25(12):2165–71.  592 
41.  Malin SK, Braun B. Effect of metformin on substrate utilization after exercise training 593 
in adults with impaired glucose tolerance. Appl Physiol Nutr Metab. 2013;38(4):427–594 
30.  595 
42.  UKPDS. Intensive blood glucose control with sulphonylureas or insulin compared with 596 
conventional treatment and risk of complications in patients with type 2 Diabetes 597 
(UKPDS 33) Diabetes. Lancet. 1998;352(9131):837–53.  598 
43.  Richter EA, Derave W, Wojtaszewski JFP. Topical Review Glucose , exercise and 599 
insulin : emerging concepts. Physiology. 2001;313–22.  600 
44.  Asano RY, Sales MM, Browne RA, Moraes JF, Coelho Junior HJ, Moraes MR, et al. 601 
Acute effects of physical exercise in type 2 diabetes: A review. World J Diabetes. 602 
2014;5(5):659–65.  603 
45.  Soydan N, Bretzel RG, Fischer B, Wagenlehner F, Pilatz A, Linn T. Reduced capacity 604 
of heart rate regulation in response to mild hypoglycemia induced by glibenclamide 605 
and physical exercise in type 2 diabetes. Metabolism. 2013;62(5):717–24.  606 
46.  Larsen JJ, Dela F, Madsbad S, Vibe-Peterson J, Galbo H. Interaction of sulfonylurea 607 
and exercise on glucose homeostasis in Type 2 diabetic patients. Diabetes Care. 608 
1999;22(10):1647–54.  609 
47.  Massi-Benedetti M, Herz M, Pfeiffer C. The Effects of Acute Exercise on Metabolic 610 
Control in Type II Diabetic Patients Treated with Glimepiride or Glibenclamide. Horm 611 
Metab Res. 1996;28(09):451–5.  612 
48.  Azoulay L, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: 613 
A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes 614 
Care. 2017;40(5):706–14.  615 
49.  Chen Y, Du L, Geng X, Peng Y, Shen J, Zhang Y, et al. Effects of sulfonylureas on 616 
lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J 617 
Evid Based Med. 2015;8(3):134–48.  618 
50.  Preiss D, Haffner SM, Thomas LE. Change in levels of physical activity after diagnosis 619 
of type 2 diabetes : an observational analysis from the NAVIGATOR study. Diabetes, 620 
Obes Metab. 2014;16(12):1265–8.  621 
51.  Consoli A, Formoso G. Do thiazolidinediones still have a role in treatment of type 2 622 
diabetes mellitus? Diabetes Obes Metab. 2013;15(11):967–77.  623 
52.  Schöndorf T, Ph D, Pfützner A, Ph D, Lübben G, Karagiannis E, et al. Pioglitazone 624 
Improves Metabolic Markers in Patients with. 2008;2(2):244–9.  625 
53.  Clarke GD, Solis-herrera C, Molina-wilkins M, Martinez S, Merovci A, Cersosimo E, 626 
et al. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With 627 
Diabetes. 2017;40(3):12–6.  628 
54.  Regensteiner JG, Bauer TA, Reusch JEB. Rosiglitazone Improves Exercise Capacity in 629 
Individuals With Type 2 Diabetes. Diabetes Care. 2005 Dec 1;28(12):2877–83.  630 
55.  Mensberg P, Nyby S, Jørgensen PG, Storgaard H, Jensen MT, Sivertsen J, et al. Near-631 
normalization of glycaemic control with glucagon-like peptide-1 receptor agonist 632 
treatment combined with exercise in patients with type 2 diabetes. Diabetes, Obes 633 
Metab. 2017;19(2):172–80.  634 
56.  Kumarathurai P, Anholm C, Nielsen OW, Kristiansen OP, Mølvig J, Madsbad S, et al. 635 
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function 636 
in patients with coronary artery disease and type 2 diabetes: A randomized double-637 
blind placebo-controlled crossover study. Cardiovasc Diabetol. 2016;15(1):1–10.  638 
57.  Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. 639 
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med [Internet]. 640 
2016;375(4):311–22. Available from: 641 
http://www.nejm.org/doi/10.1056/NEJMoa1603827 642 
58.  Scalzo RL, Moreau KL, Ozemek C, Herlache L, McMillin S, Gilligan S, et al. 643 
Exenatide improves diastolic function and attenuates arterial stiffness but does not alter 644 
exercise capacity in individuals with type 2 diabetes. J Diabetes Complications. 645 
2017;31(2):449–55.  646 
59.  Li Y, Xiao J, Tian H, Pei Y, Lu Y, Han X, et al. The DPP-4 inhibitor MK0626 and 647 
exercise protect islet function in early pre-diabetic kkay mice. Peptides. 2013;49:91–9.  648 
60.  List JF, Tang W, Woo V, Fiedorek FT, Morales E. Sodium-Glucose Cotransport 649 
Inhibition. Emerg Treat Technol. 2009;32:650–7.  650 
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 670 
Table 1: Combination effect of Drug class + exercise 671 
Drug + Exercise Glycaemic Control Exercise Tolerance Cardiovascular Disease Risks 
Biguanides 
Pre-Diabetes 
 
Insulin sensitivity ↑↑; 
Glucose ↔ 
HR ↔ BW ↓; BMI ↓ 
T2DM HbA1c ↓; glucose ↔ 
VO2 ↑↑; HR ↑↑; Lactate ↑↑ 
 
BW ↓; Lipids ↓↓ 
Sulfonylureas Hypoglycaemia ↑↑; Glucose ↓ VO2 ↔; HR ↔; Lactate ↔ Lipids (↓); BW (↓) 
Glinides Glucose ↓ (↔) (↔) 
Thiazolidinediones HbA1c ↓ HR ↓; VO2 ↑ Lipids (↓); BP ↓ 
GLP-1  
Receptor Agonists 
HbA1c ↓; Fasting glucose ↓ VO2 ↑; HR ↑ Lipids ↓; BW ↓; FFM ↓ 
DPP-4 inhibitors Glucose (↓) (↔) BW (↓) 
SGLT-2 inhibitors HbA1c (↓); Glucose (↓) HR (↔) Lipids (↓) (↓) 
↑: increase, ↑↑: strong increase, ↓: decrease, ↓↓: strong decrease, ↔: ambiguous results. BMI: Body Mass Index, BP: Blood Pressure, BW: Body Weight, FM: 672 
Free Fat Mass, HR: Heart Rate, T2DM: Type 2 Diabetes Mellitus, VO2: oxygen uptake. Brackets indicate a relative lack of evidence. 673 
